



DIGNITANA

Clinically superior scalp cooling

Q1  2019
INTERIM REPORT

Contents

Results and financial position	3
CEO comments	5
The company	6
The market	7
Business model	9
The product and product development	10
Financial information and comments	11
Forward-looking statements	13
Risk factors	13
The share	13
Board assurance	14
Financial figures	
Income Statement – Dignitana Group	15
Balance Sheet – Dignitana Group	16
Changes in Equity – Dignitana Group	18
Statement of Cash Flows – Dignitana Group	19
Income Statement – Dignitana AB, Parent Company	20
Balance Sheet – Dignitana AB, Parent Company	21
Policies for preparation of the financial report	23
Financial calendar	23
Contact information	23



Results and financial position

Significant events during the period

- Sales and other income for the period amounted to 10,106 TSEK, \$1,102 KUSD, an increase of 69 percent compared to the same period in 2018 and a 15 percent quarter over quarter growth compared to fourth quarter 2018.
- EBITDA amounted to (2,799) TSEK, (\$305) KUSD, a 59 percent improvement compared to the same period in 2018.
- Contracts were signed for 22 locations globally, bringing the total number of sites in the U.S. to 125 in 29 states at the close of first quarter.
- Dignitana announced receipt of CE Marking approval for European sales of the new DigniCap Delta device.
- As a result of the rights and directed equity issues in December, Dignitana now has 48,599,155 shares registered at Swedish Companies Registration Office.
- Dignitana announced a partnership with oneservice GmbH, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

Significant events after the period

- Contracts for 19 units were executed globally, including an order of 5 units for Kuwait, bringing the total of number of sites in the U.S. to 129 in 29 states.
- FDA review of the 510(k) application for DigniCap Delta is ongoing with clearance expected late summer 2019.

Financial results in brief

Key Ratios

DIGNITANA GROUP	Q1 2019	Q1 2018	Full year 2018
Net revenues, TSEK	9,237	5,897	33,742
Total revenues TSEK	10,106	5,988	34,075
Net profit after financial items, TSEK	(5,270)	(8,950)	(25,846)
Cash and bank balances, TSEK	21,715	22,185	22,161
Earnings per share before and after dilution, SEK	(0.11)	(0.22)	(0.66)

DIGNITANA AB	Q1 2019	Q1 2018	Full year 2018
Net revenues, TSEK	6,220	4,444	24,849
Total revenues TSEK	7,090	4,535	25,392
Net profit after financial items, TSEK	(5,286)	(9,027)	(25,796)
Cash and bank balances, TSEK	17,085	19,636	19,519

CEO comments

Dignitana is now ready to launch our new system, DigniCap Delta, as we have received CE Marking approval for Europe and the FDA clearance for the United States is expected late this summer. This new device is smaller, simpler to use and will provide improved patient outcomes. It will also provide Dignitana with a new revenue stream as DigniCap Delta uses disposable, single patient caps. A recurring revenue stream from disposables is new to the Company.

We have moved through a turnaround phase and are now seeing meaningful growth in our core business. The company is showing higher revenues and lower operating losses compared to previous years. The overall revenue trend in the critical U.S. market continues to build with Dignitana reporting record revenues this quarter. Additionally, the pace of contract signings during the first quarter affirms the increasing awareness and demand for scalp cooling as an important therapy option for patients. Orders from customers and distributors outside the U.S. also continue to increase with sales occurring across multiple countries and continents.

This next generation device is the product of more than a year of design and development and the new device significantly improves the way scalp cooling is delivered. Dignitana was first to receive FDA clearance of a scalp cooling system in the US. As we were the first scalp cooling provider on the market, we have collected useful data by listening to our customers feedback and suggestions. Based on that we have created a device that will fit seamlessly into their workflow and be easier for nurses and patients to use. The streamlined DigniCap Delta is 54 percent smaller than our previous model and the intuitive user interface provides up to 80 percent reduction in nursing time versus the existing device. These are significant upgrades that will fundamentally change the way clinicians think about and deliver scalp cooling to their patients. Additionally, the caps are for single patient use, a feature highly appreciated among patients and more user friendly for nurses. The new device includes an inner cap that provides a closer fit and even cooling across all head shapes. Patients report that DigniCap Delta is more comfortable during treatment than existing scalp cooling caps.

During the first quarter 2019 we continue to see growth in utilization of DigniCap at our locations in the United States which is a key component to the

pay-per-treatment portion of our revenue model.

The pace of sales has accelerated both in the U.S. and worldwide, providing a solid foundation for continued growth and higher utilization rates once Delta can be marketed.

In Asia, our clinical trial in Beijing is ongoing and will provide additional and valued patient data to increase our understanding of scalp cooling for the very important Asian demographic. Our partnership with Konica Minolta is progressing and we anticipate submitting the new Delta unit for PMDA clearance during the third quarter of this year.

In the United Arab Emirates, we have shipped five C3 units as a direct result of meetings at a trade show in Dubai this past January. This sale is noteworthy as the company believes there is substantial growth potential in the important Middle East market.

We are exploring financial options that will enable us to efficiently support a successful and significant global rollout of DigniCap Delta. We are committed to maintaining Dignitana's position as the leader in clinically superior scalp cooling. A combination of innovation, hard work, and a product that delivers superior patient outcomes have led us this far. Now begins the next phase of growth for this company and I am confident that our team and our new Delta unit will enable us to realize the tremendous potential this market offers.



William Cronin, CEO
Dignitana AB



The company

Dignitana is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North. The company develops, produces and markets The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. DigniCap has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety and acceptable patient comfort. In 2017 Dignitana received an expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues.





The market

Cancer is a leading cause of death worldwide and the number of people who develop cancer is continuing to increase. According to the American Cancer Society, 17 million people are diagnosed with cancer annually. One of the most common treatments for cancer is chemotherapy. Globally an estimated 20,000 clinics offer chemotherapy, providing over ten million chemotherapy treatments per year. The side effects of chemotherapy can make treatment very difficult. As a visible reminder of the disease, hair loss is often identified as one of the most distressing side effects. Physicians estimate that approximately ten percent of patients decline the prescribed chemotherapy out of fear of losing their hair.

Dignitana's DigniCap Scalp Cooling System is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide. The World Cancer Research Fund reports over 1.5 million diagnosed cases of breast cancer annually. Dignitana estimates that 60 percent of breast cancer patients can be treated with The DigniCap Scalp Cooling System. In addition, the American Cancer Society reports that in the U.S. each year approximately 1.3 million patients are diagnosed with solid tumor cancers. Many of these patients are on regimens compatible with DigniCap.

The DigniCap Scalp Cooling System was invented in Sweden and has been marketed since 2001. It is now available in Asia, Australia, Europe, the Middle East, North America and South America. The United States is the leading market for medical devices in the world. The sales model in the U.S. involves diversified revenue sources with pay-per-treatment revenue as the largest contributing source.


In the United States, the company is focused on optimizing revenue from existing locations. In order to maximize our resource utilization Dignitana has relocated machines from several non- or low-performing sites to high-demand locations. In the first quarter, 12 contracts were signed bringing the total number of U.S. locations to 125. Multiple site practices continue to be a priority, with one new master agreement and 5 of the new first quarter locations joining under existing master agreements.

Global revenues have increased by 69 percent over same period 2018 as a result of increased interaction with direct customers and global distributors. During the first period, 10 units were sold to customers in Germany, Italy, Israel and the Middle East. DigniCap interest in Europe continues to build, and our partnership with

oneservice GmbH to provide localized service and maintenance has been an efficient and effective way for European customers to receive prompt assistance and support.

Dignitana's distribution partners in the Middle East, Australia and Mexico have ramped up sales efforts and are beginning to introduce DigniCap Delta to their regions now that the CE Marking has been received. In Asia, the clinical trial at Beijing University Cancer Hospital is ongoing, representing the first clinical evaluation of scalp cooling on an exclusively Asian population. It will provide valuable clinical data to identify and support new market growth opportunities. Dignitana continues to work with Konica Minolta and we anticipate submitting the new Delta unit for PMDA clearance in Japan during the third quarter of this year.


Accelerating Pace of Contract Signings (37 v. 12)





Business model

The company has four primary revenue streams: treatment fees to patients (pay-per-treatment using leased machines); machine sales; service agreements; and leasing fees. In the United States the largest opportunity for growth is through the pay-per-treatment model. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



The product and product development

The DigniCap Scalp Cooling System has been clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumor cancers. The current DigniCap model has been on the market since 2009.

In addition to occasional software upgrades, recent enhancements to the system include the DigniTherm Click Cap, a product extension engineered to improve ease of use and enhance cap fit to improve patient outcomes. The U.S. launch of the Click Cap was completed in March 2018, and the remainder of 2018 showed a steady increase in utilization as facilities used the new cap and became familiar with the improvements.

The launch of DigniCap Delta, the next generation scalp cooling device, is now underway. Dignitana received CE Marking approval for the new device in March allowing the initiation of DigniCap Delta sales in Europe. The first installation of DigniCap Delta is already scheduled in Europe. FDA clearance is pending, and Dignitana will initiate sales in the United States as soon as clearance is granted which is expected sometime late this summer. DigniCap Delta is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients.



Financial information and comments

Group revenues are generated by direct sales of systems, pay-per-treatment fees, leased machines, service agreements and other revenue such as spare parts sales. Dignitana Group revenues were 10,106 TSEK, \$1,102 KUSD, an increase of 69 percent compared to the same period in 2018 as a result of management's initiative to increase direct customer interaction and global distributors as well as a focus on optimizing revenue at existing locations in the US. Additionally, Dignitana AB sold a patent to BrainCool in the first quarter. The patent sale is included in Other Income for the Group.

Dignitana revenues and costs are comprised of different currencies such as U.S. Dollars, Euros, SEK, and other currencies. Foreign exchange translation differences are found on the income statement under results from financial investments.

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the


U.S. market Dignitana does not sell the device directly to the end customer as various lease models are employed.

A large portion of operations were moved from Sweden to the U.S. in the first quarter of 2018. This move resulted in a (1,560) TSEK decrease in operating expenses for the Group from the prior year to 10,742 TSEK for the first quarter of 2019.

As a result of the strong year over year growth in revenue and the year over year reduction in operating expenses, Group EBIT was (4,710) TSEK a 46 percent improvement from (8,785) TSEK in the same period in 2018. Net profit after financial items improved to (5,270) TSEK compared to the same period last year (8,950) TSEK.

In January, the additional and final proceeds were received from the rights and equity offerings. These proceeds will fund operations as well as the completion of the development of DigniCap Delta. The cash and balances amounted to 21,715 TSEK due to the successful rights offerings and directed issues.

Revenues Per Quarter – Dignitana, Inc. (USD)





Parent Company

Parent revenues are generated by direct sales of systems, leased machines, service agreements and other revenue such as spare parts sales. Dignitana AB revenues were 7,090 TSEK, an increase of 56 percent compared to the same period in 2018 as a result of management's initiative to increase direct customer interaction and sales to global distributors. Additionally, the Parent Company sold a patent to BrainCool in the first quarter. This patent sale is included in Other Income for the Parent Company.

The Parent Company revenues and costs are comprised of different currencies such as Euros, SEK, and other currencies. Foreign exchange translation differences are found on the income statement under results from financial investments.

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer.

A large portion of operations were moved from Sweden to the US in the first quarter of 2018. This move resulted in a 2,185 TSEK decrease in operating expenses for the Parent from the prior year to 9,081 TSEK for the first quarter of 2019.

As a result of the strong year over growth in revenue and the year over year reduction in operating expenses, Parent EBIT was (4,937) TSEK an improvement from (9,171) TSEK in the same period in 2018. Net profit after financial items improved to (5,286) TSEK compare to the same period last year (9,026) TSEK.

Staff

Dignitana Group Number of Staff is 23.

Dignitana AB Number of Staff is 2.

Forward-looking statements

This report may contain statements, estimates or projections that constitute “forward-looking statements”. Generally, the words “believe”, “expect”, “intend”, “estimate”, “anticipate”, “project”, “will” and similar expressions identify forward-looking statements, which

generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Risk factors

An investment in securities is associated with risk. Dignitana’s activities are affected, and may be affected, by a number of factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

Following, without any particular order and without claim to be exhaustive, are some of the risk factors and circumstances which are considered essential for Dignitana’s operations and future development. The risks described are not a conclusive list of the risks to which the Company and its shareholders may be exposed. Additional risks that are not currently known to the Company or that the Company currently does not consider essential may also be of significant importance to Dignitana’s business, financial position and results. Such risks may also cause the Company’s share price to fall sharply and investors may lose all or part of their

investment. In addition to this section, investors should also consider the other information contained in the Prospectus as a whole and implement one general environmental assessment.

The non-conclusive list of the Company’s risks concerns (but are not limited to):

Patents, Key Personnel, Growth Management, Restructuring, Development Costs, Competitors, Capital Bonds, Dependence on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the December 2018 Company Prospectus posted at <https://investor.dignitana.com/new-issues/>

The share

The total number of outstanding shares at the close of the first period 2019 was 48,599,155.

The share has been listed on Nasdaq First North since 30 November 2011 after having been listed at Aktietorget since June 2009. It is traded under the DIGN ticker.

There are 265,000 warrants in the company. The warrants carry the right to purchase 165,000 shares in the period June 1 to 30, 2019 and 100,000 shares in the period June 1 to 30, 2020 and will, on full exercise, increase the company share capital by SEK 265,000.

Erik Penser Bank is the company’s Certified Adviser.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 15 May 2019

Dignitana AB (publ) Board of Directors

Thomas Kelly
Chairman

William Cronin
Director and CEO

Mikael Wahlgren
Director and
Deputy Managing Director

Ingrid Atteryd Heiman
Director

This interim report has not
been audited by the company auditors.

Income Statement – Dignitana Group

SEK

DIGNITANA GROUP	Q1 2019	Q1 2018	Full year 2018
Operating Income			
Revenue	9,236,624	5,896,731	33,742,077
Own work capitalized	-	-	-
Other income	869,820	90,962	332,827
Total Operating Income	10,106,445	5,987,693	34,074,904
Cost of Goods Sold			
Goods for Resale	2,163,480	504,576	4,085,592
Gross Profit	7,942,965	5,483,117	29,989,312
Operating expenses			
Operating Expense	6,070,590	6,648,222	26,358,173
Personnel expenses	4,659,636	5,644,180	19,555,853
Other Operating expense	12,228	10,337	29,160
Total operating expenses	10,742,453	12,302,739	45,943,187
Operating profit (loss) – EBITDA	(2,799,488)	(6,819,622)	(15,953,874)
Depreciation of tangible and intangible assets	1,910,581	1,964,970	8,066,961
Operating profit (loss) after depreciation – EBIT	(4,710,070)	(8,784,592)	(24,020,835)
Result from financial investments			
Interest income and similar items	838	386,733	598,895
Interest expenses and similar items	(560,508)	(552,597)	(2,423,667)
Total income (loss) from financial investments	(559,670)	(165,864)	(1,824,772)
Net profit (loss) after financial items	(5,269,740)	(8,950,456)	(25,845,607)
Corporate Taxes	51,123	1,907	175,753
Results for the Period	(5,320,863)	(8,952,363)	(26,021,360)
Total shares at the period-end before and after dilution ¹	48,599,155	40,548,224	40,548,224
Average number of shares before and after dilution ¹	48,599,155	40,548,224	39,492,859
Earnings per share before and after dilution ¹	(0.11)	(0.22)	(0.66)

1) no dilution

Balance Sheet – Dignitana Group

SEK

STATEMENT OF FINANCIAL POSITION	2019-03-31	2018-03-31	2018-12-31
Fixed Assets			
<u>Intangible assets</u>			
Capitalized expenses for development, net	20,837,601	10,840,528	19,029,429
<u>Tangible assets</u>			
Equipment, tools and installations, net	13,779,388	18,599,895	14,747,076
Total Fixed Assets	34,616,990	29,440,424	33,776,505
Current Assets			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6,350,621	2,198,515	6,308,536
Advance payment to suppliers	0	0	0
	6,350,621	2,198,515	6,308,536
<u>Current Receivables</u>			
Accounts Receivable	7,469,009	3,098,316	7,317,979
Current Tax Assets	6,825	22,452	88,551
Other current receivables	348,063	0	9,846,053
Prepaid expenses and accrued income	959,557	1,278,678	875,257
	8,783,454	4,399,446	18,127,839
<u>Cash and Bank Balances</u>	21,715,092	22,185,170	22,160,876
Total Current Assets	36,849,168	28,783,131	46,597,251
Total Assets	71,466,157	58,223,554	80,373,757

Balance Sheet – Dignitana Group, continued

SEK

STATEMENT OF FINANCIAL POSITION	2019-03-31	2018-03-31	2018-12-31
Equity and Liabilities			
Equity			
<u>Restricted equity</u>			
Share Capital			
(48,599,155 shares par value SEK 1, previous year 40,528,224)	48,599,155	40,548,224	40,548,224
Unregistered share capital	–	–	8,050,931
Fund for development expenses	15,398,520	2,635,796	12,899,975
	63,997,675	43,184,020	61,499,130
<u>Non-restricted equity</u>			
Other paid-in capital	(9,048,618)	7,874,945	19,487,347
Results for the period	(5,320,863)	(8,950,455)	(26,021,360)
	(14,369,480)	(1,075,510)	(6,534,013)
Total Equity	49,628,195	42,108,510	54,965,116
Current Liabilities			
Accounts payable	5,153,442	1,727,132	8,089,438
Other current liabilities	1,030,317	5,361,135	2,327,198
Liabilities to credit institutions	7,171,018	–	7,258,983
Accrued expenses and deferred income	6,289,673	4,002,673	4,804,166
Total current liabilities	19,644,449	11,090,940	22,479,785
Long Term Liabilities			
Liabilities to credit Institutions	2,193,513	5,024,104	2,928,856
Total Equity and Liabilities	71,466,157	58,223,554	80,373,757

Changes in Equity – Dignitana Group

SEK

	Q1 2019	Q1 2018	Full Year 2018
Opening balance	54,965,116	51,145,960	51,145,960
New Share Issue			
Unregistered Share Issue			33,813,912
Issue expenses			(3,971,913)
Subscribed warrants			
Translation difference on consolidation Results for the period	(16,058)	(86,995)	(1,482)
Results through the end of the period	(5,320,863)	(8,950,455)	(26,021,360)
Closing balance	49,628,195	42,108,510	54,965,116

Statement of Cash Flows – Dignitana Group

SEK

	Q1 2019	Q1 2018	Full Year 2018
Operating Activities			
Operating income before financial items	(4,710,070)	(8,784,592)	(24,020,835)
Adjustments for items not affecting cash flows	1,910,581	1,964,970	8,066,961
Interest received	838	386,733	598,895
Interest paid	(560,508)	(552,597)	(2,423,667)
Income tax paid	(81,726)	–	(51,575)
	(3,440,885)	(6,985,486)	(17,830,221)
Changes in inventories	(42,085)	645,320	(3,464,701)
Changes in other current receivables	(583,394)	704,620	(3,309,049)
Changes in other current liabilities	(2,222,371)	(9,182,257)	3,972,605
Cash flows from operating activities	(6,288,735)	(14,817,802)	(20,631,367)
Investing Activities			
Acquisition of fixed assets	(2,751,065)	(649,630)	(11,087,702)
Cash flows from investing activities	(2,751,065)	(649,630)	(11,087,702)
Financing Activities			
New share issue	9,846,053	42,575,635	66,542,504
Issuance costs	(525,000)	(93,577)	(7,927,913)
Subscribed warrants	–	–	–
Long Term Liabilities	(823,307)	(5,853,996)	(5,690,262)
Cash flows from financial activities	8,497,746	36,628,062	52,924,329
Cash flows in the period	(542,055)	21,160,630	21,205,260
Cash and cash equivalents at start of the period	22,160,875	1,017,957	1,017,957
Translation difference on cash and cash equivalents	96,271	6,583	(62,342)
Cash and cash equivalents Period End	21,715,092	22,185,170	22,160,875

Income Statement – Dignitana AB, Parent Company

SEK

DIGNITANA AB, PARENT COMPANY	Q1 2019	Q1 2018	Full year 2018
Operating Income			
Revenue	6,220,499	4,443,818	24,848,578
Own work capitalized	–	–	–
Other income	869,820	90,962	543,547
Total Operating Income	7,090,319	4,534,780	25,392,126
Cost of Goods Sold			
Goods for Resale	1,096,358	504,576	4,085,592
Gross Profit	5,993,961	4,030,204	21,306,533
Operating expenses			
Other external expenses	8,562,077	9,456,456	34,972,918
Personnel expenses	506,570	1,799,342	3,671,013
Other Operating expense	12,228	10,337	(125,763)
Total operating expenses	9,080,875	11,266,135	38,518,168
Operating profit (loss) – EBITDA	(3,086,914)	(7,235,931)	(17,211,634)
Depreciation and amortization	1,850,414	1,935,275	7,884,010
Operating profit (loss) after depreciation – EBIT	(4,937,327)	(9,171,207)	(25,095,645)
Result from financial investments			
Interest (income) and similar items	–	386,733	–
Interest expenses and similar items	(349,023)	(242,146)	(700,415)
Total income from financial investments	(349,023)	144,587	(700,415)
Net profit (loss) after financial items	(5,286,350)	(9,026,619)	(25,796,060)
Corporate Taxes	–	–	–
Results for the Period	(5,286,350)	(9,026,619)	(25,796,060)

Balance Sheet – Dignitana AB, Parent Company

SEK

STATEMENT OF FINANCIAL POSITION	2019-03-31	2018-03-31	2018-12-31
Fixed Assets			
<u>Intangible assets</u>			
Capitalized expenses for development, net	20,820,171	10,765,402	19,011,353
<u>Tangible assets</u>			
Equipment, tools and installations, net	13,180,557	18,306,391	14,229,631
<u>Financial assets</u>			
Participations in group companies	522,094	420,010	522,094
Total Fixed Assets	34,522,822	29,491,804	33,763,078
Current Assets			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6,350,621	2,198,515	6,308,536
Advance payment to suppliers	0	0	0
	6,350,621	2,198,515	6,308,536
<u>Current Receivables</u>			
Accounts Receivable	2,536,381	166,317	2,130,336
Current Receivables from group companies	1,408,114	0	905,822
Current Tax Assets	6,825	73	88,551
Other current receivables	342,417	0	9,846,053
Prepaid expenses and accrued income	487,065	544,143	450,202
	4,780,801	710,533	13,420,965
Cash and Bank Balances	17,085,444	19,636,903	19,519,192
Total Current Assets	28,216,866	22,545,951	39,248,692
<u>Long Term Loan – group</u>	459,483	411,610	441,122
Total Assets	63,199,172	52,449,365	73,452,892

Balance Sheet – Dignitana AB, Parent Company, continued

SEK

STATEMENT OF FINANCIAL POSITION	2019-03-31	2018-03-31	2018-12-31
Equity and Liabilities			
Equity			
<u>Restricted equity</u>			
Share Capital			
(48,599,155 shares par value SEK 1, previous year 40,528,224)	48,599,155	40,548,224	40,548,224
Unregistered share capital	0	0	8,050,931
Fund for development expenses	15,398,520	2,635,796	12,899,975
	63,997,675	43,184,020	61,499,130
<u>Non-restricted equity</u>			
Retained Earnings	(48,000,280)	7,994,421	(19,705,674)
Share premium reserves	48,064,504	–	48,064,504
Issue expense	(8,743,945)	–	(8,743,945)
Results for the period	(5,286,350)	(9,026,620)	(25,796,060)
	(13,966,071)	(1,032,199)	(6,181,175)
Total Equity	50,031,605	42,151,821	55,317,955
Current Liabilities			
Accounts payable	2,890,566	1,083,339	5,678,280
Other current liabilities	0	399,804	–
Liabilities to credit institutions	0	0	–
Current payable to group company	4,376,221	5,004,886	7,374,249
Accrued expenses and deferred income	4,873,250	3,809,514	4,054,879
Total current liabilities	12,140,037	10,297,543	17,107,408
Long Term Liabilities			
Liabilities to Credit Institutions	1,027,530	–	1,027,530
Total Equity and Liabilities	63,199,172	52,449,365	73,452,892

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

22 August 2019	Q2 Interim Report through 30 June 2019
21 November 2019	Q3 Interim Report through 30 September 2019
25 February 2020	2019 Year End Report
13 May 2020	Annual General Meeting

All financial reports are available at **www.dignitana.se**

Contact information

Dignitana AB

Traktörgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
www.dignitana.se
info@dignitana.se
investorrelations@dignitana.com

Certified Adviser

Erik Penser Bank AB
+46 (0) 8 463 83 00
certifiedadviser@penser.se
www.penser.se